Abstract No. 520 Liver-directed treatments of liver-dominant metastatic leiomyosarcoma

Leiomyosarcomas are malignant tumors of smooth muscle origin. Response to chemotherapy is low with a median overall survival (OS)of 26.5 months when treated with olaratumab and doxorubicin (1). Surgical metastatectomy achieved 61.6 months median OS, but the majority of patients are not resectable (2). Liver metastasis is often the limiting factor for survival. The use of liver directed treatment is of clinical interest. The purpose of this study was to determine the safety and efficacy of transarterial chemoembolization (TACE), yttrium-90 (Y90) radioembolization, and percutaneous ablation in patients with unresectable metastatic leiomyosarcoma to the liver.

Source: Journal of Vascular and Interventional Radiology : JVIR - February 23, 2019 Category: Radiology Authors: H. Krzyston, D. Deperalta, R. Kayaleh, B. Morse, G. El-Haddad, J. Smith, M. Druta, B. Kis Tags: Scientific e-Posters Source Type: research